Table 1 Association of TSTA3 mRNA levels with clinicopathological factors in patients with LUSC and LUAD in TCGA
Variables | Case | LUSC | Case | LUAD | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | Low (%) | High (%) | X2 | P | n | Low (%) | High (%) | X2 | P | |
Age (years) | ||||||||||
 < 60 | 84 | 33 (19.5%) | 51 (16.5%) | 0.689 | 0.451 | 134 | 116 (28.1%) | 18 (26.1%) | 0.118 | 0.731 |
 ≥ 60 | 394 | 136 (80.5%) | 258 (83.5%) |  |  | 348 | 297 (71.9%) | 51 (73.9%) |  |  |
Gender | ||||||||||
 Female | 126 | 37 (21.9%) | 89 (28.8%) | 2.687 | 0.105 | 263 | 230 (55.7%) | 33 (47.8%) | 1.475 | 0.225 |
 Male | 352 | 132 (78.1%) | 220 (71.2%) |  |  | 219 | 183 (44.3%) | 36 (52.2%) |  |  |
Smoking history | ||||||||||
 Never | 18 | 5 (3.0%) | 13 (4.2%) | 0.470 | 0.619 | 264 | 229 (55.4%) | 35 (50.7%) | 0.532 | 0.466 |
 Current | 460 | 164 (97.0%) | 296 (95.8%) |  |  | 218 | 184 (44.6%) | 34 (49.3%) |  |  |
T stage | ||||||||||
 T1 | 106 | 39 (23.1%) | 67 (21.7%) | 7.653 | 0.022 | 165 | 148 (35.8%) | 17 (24.6%) | 4.073 | 0.130 |
 T2 | 284 | 110 (65.1%) | 174 (56.3%) |  |  | 257 | 217 (52.5%) | 40 (58.0%) |  |  |
 T3 + T4 | 88 | 20 (11.8%) | 68 (22.0%) |  |  | 60 | 48 (11.6%) | 12 (17.4%) |  |  |
N stage | ||||||||||
 Yes | 168 | 63 (62.7%) | 105 (66%) | 0.521 | 0.470 | 163 | 141 (34.1%) | 22 (31.9%) | 0.134 | 0.714 |
 No | 310 | 106 (37.3%) | 204 (34%) |  |  | 319 | 272 (65.9%) | 47 (68.1%) |  |  |
Clinical stage | ||||||||||
 I | 236 | 84 (49.7%) | 152 (49.2%) | 8.197 | 0.017 | 261 | 222 (53.8%) | 39 (56.5%) | 2.918 | 0.232 |
 II | 153 | 64 (37.9%) | 89 (28.8%) |  |  | 120 | 108 (26.2%) | 12 (17.4%) |  |  |
 III + IV | 89 | 21 (12.4%) | 68 (22.0%) |  |  | 79 | 83 (20.1%) | 18 (26.1%) |  |  |